185 related articles for article (PubMed ID: 26425548)
1. Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma.
Tusé D; Ku N; Bendandi M; Becerra C; Collins R; Langford N; Sancho SI; López-Díaz de Cerio A; Pastor F; Kandzia R; Thieme F; Jarczowski F; Krause D; Ma JK; Pandya S; Klimyuk V; Gleba Y; Butler-Ransohoff JE
Biomed Res Int; 2015; 2015():648143. PubMed ID: 26425548
[TBL] [Abstract][Full Text] [Related]
2. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
[TBL] [Abstract][Full Text] [Related]
3. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
Hurvitz SA; Timmerman JM
Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
5. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy R; Ganjoo KN; Leonard JP; Vose JM; Flinn IW; Ambinder RF; Connors JM; Berinstein NL; Belch AR; Bartlett NL; Nichols C; Emmanouilides CE; Timmerman JM; Gregory SA; Link BK; Inwards DJ; Freedman AS; Matous JV; Robertson MJ; Kunkel LA; Ingolia DE; Gentles AJ; Liu CL; Tibshirani R; Alizadeh AA; Denney DW
J Clin Oncol; 2014 Jun; 32(17):1797-803. PubMed ID: 24799467
[TBL] [Abstract][Full Text] [Related]
6. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
7. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
8. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L. W. Kwak.
Schumacher K
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R10-3. PubMed ID: 11768618
[No Abstract] [Full Text] [Related]
9. Prolonged idiotypic vaccination against follicular lymphoma.
Inoges S; Lopez-Diaz de Cerio A; Zabalegui N; Soria E; Villanueva H; Panizo C; Rodriguez-Caballero A; Suarez L; Pastor F; Rodriguez-Calvillo M; Orfao A; Bendandi M
Leuk Lymphoma; 2009 Jan; 50(1):47-53. PubMed ID: 19152172
[TBL] [Abstract][Full Text] [Related]
10. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
[TBL] [Abstract][Full Text] [Related]
12. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines.
Kafi K; Betting DJ; Yamada RE; Bacica M; Steward KK; Timmerman JM
Mol Immunol; 2009 Jan; 46(3):448-56. PubMed ID: 19046770
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.
Timmerman JM; Vose JM; Czerwinski DK; Weng WK; Ingolia D; Mayo M; Denney DW; Levy R
Leuk Lymphoma; 2009 Jan; 50(1):37-46. PubMed ID: 19125383
[TBL] [Abstract][Full Text] [Related]
14. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
15. Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
Neelapu SS; Baskar S; Kwak LW
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R14-9. PubMed ID: 11768619
[TBL] [Abstract][Full Text] [Related]
16. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
17. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
Front Immunol; 2019; 10():2497. PubMed ID: 31708925
[No Abstract] [Full Text] [Related]
20. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M; Rodríguez-Calvillo M; Inogés S; López-Díaz de Cerio A; Pérez-Simón JA; Rodríguez-Caballero A; García-Montero A; Almeida J; Zabalegui N; Giraldo P; San Miguel J; Orfao A
Leuk Lymphoma; 2006 Jan; 47(1):29-37. PubMed ID: 16321824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]